{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ji Y"],"funding":["NCI NIH HHS"],"pagination":["4093-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4669593"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(34)"],"pubmed_abstract":["<h4>Purpose</h4>Progesterone receptors are expressed in approximately 70% of meningiomas. Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II study. This multicenter, prospective, randomized, placebo-controlled phase III trial conducted by SWOG was planned to define the role of mifepristone in the treatment of unresectable meningioma.<h4>Patients and methods</h4>Eligible patients were randomly assigned to receive either mifepristone or placebo for 2 years unless disease progressed. Patients who were stable or responding to protocol therapy after 2 years had the option to continue with the same blinded therapy. Serial follow-up allowed assessment of efficacy and toxicity. Time to treatment failure and overall survival were ascertained for all rand"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005."],"pmcid":["PMC4669593"],"funding_grant_id":["U10 CA035176","CA180835","CA180834","U10 CA035431","N01 CA035119","CA180830","U10 CA073590","U10 CA035192","CA67663","N01 CA045560","U10 CA020319","CA45461","U10 CA046282","U10 CA180830","CA180819","U10 CA180834","U10 CA035119","U10 CA067663","CA180818","U10 CA180835","CA73590","CA180858","CA02115","N01 CA035431","U10 CA180858","CA35192","N01 CA035176","CA180888","CA58882","N01 CA013612","CA180846","U10 CA180818","U10 CA013612","U10 CA180819","CA180801","CA180820","CA46282","U10 CA058882","U10 CA180820","U10 CA180801","UG1 CA180830","U10 CA180846","U10 CA180888","CA20319","U10 CA045560","U10 CA045461"],"pubmed_authors":["Grunberg S","Russell CA","Verschraegen C","Fredericks RK","Kabbinavar FF","Schott A","Ahmadi J","Rankin C","Sherrod AE","Townsend JJ","Feun LG","Ji Y","Stelzer KJ"],"additional_accession":[]},"is_claimable":false,"name":"Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.","description":"<h4>Purpose</h4>Progesterone receptors are expressed in approximately 70% of meningiomas. Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II study. This multicenter, prospective, randomized, placebo-controlled phase III trial conducted by SWOG was planned to define the role of mifepristone in the treatment of unresectable meningioma.<h4>Patients and methods</h4>Eligible patients were randomly assigned to receive either mifepristone or placebo for 2 years unless disease progressed. Patients who were stable or responding to protocol therapy after 2 years had the option to continue with the same blinded therapy. Serial follow-up allowed assessment of efficacy and toxicity. Time to treatment failure and overall survival were ascertained for all rand","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Dec","modification":"2026-05-10T00:41:42.823Z","creation":"2020-10-29T10:35:49Z"},"accession":"S-EPMC4669593","cross_references":{"pubmed":["26527781"],"doi":["10.1200/JCO.2015.61.6490","10.1200/jco.2015.61.6490"]}}